tbuckley/cabot-search huggingface dataset:
The optimal time to determine the minimal phototoxic dose in skin photosensitized by topical 8 methoxypsoralen
Authors: I. Man, R.S. Dawe, J. Ferguson, S.H. Ibbotson
Journal: British Journal of Dermatology (2004)

Background We recently investigated the characteristics of psoralen plus ultraviolet (UV) A erythema in skin photosensitized by topical 8-methoxypsoralen (8-MOP) in three independent studies. Objectives In order to determine the optimal time to read the minimal phototoxic dose (MPD) after treatment with topical 8-MOP and irradiation with UVA, we assessed the overall data. Methods One forearm of each subject was immersed in 8-MOP solution for 15 min and test sites on the flexor surface of the forearm were immediately exposed to a UVA dose series. Erythema was assessed visually and objectively using a reflectance instrument at 24-h intervals for 7 days. Results Results were obtained from 44 subjects (predominantly Fitzpatrick skin phototype II). A broad erythemal plateau was evident beyond 72 h and the visual MPD was significantly lower at 96, 120 and 144 h than at 72 h (P < 0·01). Only 30% of subjects were at peak erythema at the conventional MPD assessment time of 72 h. The median time to reach maximal erythema was 96 h (range 48–144). Objectively, 85% of subjects were at peak erythema at or beyond 96 h. Conclusions We recommend that (i) the optimal time to read the topical 8-MOP MPD is 4 days after UVA exposure as readings beyond this time may be difficult to interpret because of the development of pigmentation, and (ii) 40% of the topical 8-MOP MPD should be considered for the first treatment.
Query necessity, cost-effectiveness of IVP to evaluate prostatism
Authors: John Elliott
Journal: JAMA (1979)

Ask any urologist. Intravenous pyelography (IVP), like kissing your spouse good-bye in the morning or brushing your teeth before going to bed, goes hand in hand with transurethral prostatectomy (TURP). The most commonly performed urologic procedure in America, TURP until now has been almost invariably preceded by IVP for detection of any pathological condition in the upper urinary tract. But a new study conducted at the University of Kentucky Medical Center in Lexington by Department of Urology chairman J. William McRoberts, MD, and urology residents Daniel L. Bauer, MD, and Robert W. Garrison, MD, indicates that in most cases IVP before TURP is probably not necessary. "When we reviewed a specially selected group of 601 patients who had had routine IVP prior to transurethral resections," explained Bauer, "we found positive results so seldom that we believe the test is not indicated and certainly not cost-effective." However, Bauer was quick to
Gynecologic Surgery: Errors, Safeguards, and Salvage
Authors: Thomas H. Green
Journal: JAMA (1975)

This is a superlative book that belongs in the library of every surgeon performing gynecologic operations. There are nine chapters covering the indications and contraindications for the principal types of gynecologic operations and emphasizing the various complications and how they develop, how to avoid them, and how to care for them should they occur. Probably no other readily available single source offers such a comprehensive discussion of the prevention and the management of all the potential complications of gynecologic surgery. The numerous drawings and photographs are excellent and well chosen to illustrate various technical points. Each section concludes with a carefully selected list of references.  A final chapter by a highly competent lawyer with long experience in the malpractice field sets forth many of the important legal points of view and contains sound advice.  This superb volume presents the collective work and extensive experience of a group of master gynecologic
Exhaled nitric oxide levels in atopic children: relation to specific allergic sensitisation, AHR, and respiratory symptoms
Authors: J D Leuppi
Journal: Thorax (2002)

<b>Background:</b> Exhaled nitric oxide (eNO), which has been proposed as a measure of airway inflammation, is increased in atopic subjects. This raises the question of whether eNO provides any additional information about airway inflammation in asthmatic subjects, other than as a marker for atopy. A study was undertaken to determine whether eNO levels in a population of atopic children are associated with sensitisation or natural exposure to specific allergens, and to examine the relationship between eNO, airway responsiveness, and current respiratory symptoms. <b>Methods:</b> Exhaled NO and airway responsiveness to histamine were measured in winter and in summer in 235 children aged 8–14 years who had been classified as atopic by skin prick testing. Current respiratory symptoms, defined as wheeze or cough during the month preceding the test, were measured by a parent completed questionnaire. Airway hyperresponsiveness (AHR) was defined as a dose response ratio (DRR) of &gt;8.1 (% fall in forced expiratory volume in 1 second (FEV<sub>1</sub>)/μmol + 3). <b>Results:</b> Sensitisation to house dust mite was associated with raised eNO levels in winter while sensitisation to <i>Cladosporium</i> was associated with raised eNO levels in both winter and summer. Grass pollen sensitisation was not associated with raised eNO levels in either season. Exhaled NO correlated significantly with DRR histamine (<i>r</i>=0.43, p&lt;0.001) independently of whether the children had current symptoms or not. In children with current wheeze, those with AHR had eNO levels 1.53 (95% CI 1.41 to 1.66) times higher than those without AHR (p=0.006). Neither DRR (p=1.0) nor eNO levels (p=0.92) differed significantly between children with or without persistent dry cough in the absence of wheeze. <b>Conclusions:</b> In atopic children, raised eNO levels are associated with sensitisation to perennial allergens, but not to seasonal allergens such as grass pollen. In this population, an increase in eNO is associated with AHR and current wheezing, suggesting that eNO is more than just a marker for atopy.
Reporting diagnostic tests
Authors: S. E Straus
Journal: BMJ (2003)

Education and debate p 41 

As a clinician, I need high quality evidence about the usefulness, precision, and accuracy of diagnostic tests, and I need it now. Such evidence is rare even for the clinical examination, the most critical component of the diagnostic process. 1 2 The situation is getting worse with the exponential increase of diagnostic tests, most of which have never been evaluated properly and can mislead the diagnostic process. Although rigorous methodological standards in research about diagnostic tests have been applied more rigorously in the past decade, their reporting and methodological quality remain inadequate.2–5 Against this background, the proposal in this issue from the authors of Standards for Reporting of Diagnostic Accuracy (STARD) for reporting diagnostic research should be applauded (p …
Influenza Vaccination in Multiple Sclerosis
Authors: William A. Sibley
Journal: JAMA (1976)

<h3>To the Editor.—</h3> Reviewing the literature on influenza vaccination the authors cited a LETTER TO THE EDITOR in<i>JAMA</i>(225:63, 1973). This letter warned of the "Hazard of Influenza Vaccine in Neurologic Patients" and, thus, might alarm physicians who treat multiple sclerosis patients during the forthcoming months when there will be the possibility of swine influenza causing extensive disease and extensive immunization may be underway. One of us (W.A.S.) had the opportunity of reviewing the details of the case presented by Dr Rabin in his letter, and we found that the letter was somewhat misleading. In summary, the patient referred to had had retrobulbar neuritis in 1961, then had attacks of pain and numbness involving the right arm, in subsequent years, for which she had neck surgery. Three months before influenza vaccination she had reported increased numbness of the right arm. In September and October 1968, she received influenza vaccination,
Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
Authors: Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini
Journal: Blood (2012)
Lys9 for Glu9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin (9–39)
Authors: B.D Green, M.H Mooney, V.A Gault, N Irwin, C.J Bailey, P Harriott, B Greer, P.R Flatt, F.P.M O’Harte
Journal: Metabolism (2004)
MISMANAGEMENT OF THE EYES OF READERS.
Authors: NORBURNE B. JENKINS
Journal: JAMA (1899)

The exact fitting of reading lenses to the eyes of studiously inclined persons past middle age, is either one of the most simple or one of the most complicated things that the oculist is ever called upon to do. In the absence of astigmatism and of a difference in the refraction of the eyes, the fitting of reading lenses is a matter of no difficulty. When there exists 0.5D. or more of astigmatism in one or both eyes, and a difference of 0.25D. or more in the refraction of the eyes perfectly fitting lenses for reading are seldom obtained. Commonly but little care is given to the fitting of reading lenses to the eyes of persons above 40 years of age. Ordinarily the weakest convex lenses with which the patient is able to read the smallest print at a distance of 22 cm. (8.5 inches) from the eyes, are prescribed.
Concentrations of Phthalate Metabolites in Milk, Urine, Saliva, and Serum of Lactating North Carolina Women
Authors: Erin P. Hines, Antonia M. Calafat, Manori J. Silva, Pauline Mendola, Suzanne E. Fenton
Journal: Environmental Health Perspectives (2008)

Phthalates are ubiquitous in the environment, but concentrations in multiple media from breast-feeding U.S. women have not been evaluated.
Abstract LB-72: Rapid detection and profiling of breast cancer cells in blood applied to arrays of carbon nanotube thin film biosensors
Authors: Balaji Panchapakesan, Vanessa Velasco, Rui-Yan Jing, Pooja Talati, Allison M. Zibelli, Eric Wickstrom
Journal: Cancer Research (2010)

Abstract Breast cancer is the most frequently diagnosed cancer in women. Developing breast cancers shed transformed cells into the blood. More malignant breast cancer cells appear in the blood at later stages. Early detection of circulating breast cancer cells might improve diagnosis of early breast cancer and ultimately might reduce deaths from breast cancer. We hypothesized that nanotube-antibody arrays could detect circulating human breast cancer cells in a drop of blood. Breast cancer cell surfaces show high levels of insulin-like growth factor 1 receptor (IGF1R), human epidermal growth factor receptor 1 (Her1, EGFR), and Her2 (Erb-B2, neu), among others. We have previously demonstrated antibody-specific nanodevice detection of ER+/Her2- MCF7 and ER+/Her2+ BT474 breast cancer cells suspended in a physiological buffer, and in fresh human blood. We discovered significant changes in conductance of single wall carbon nanotube-monoclonal antibody nanodevices upon exposure to human breast cancer cells in 2-5 microliter drops of physiological buffer or fresh donor blood. The nanodevices detected the cancer cells within 60 seconds and stabilized by five minutes. Control cells did not change nanodevice conductance. Breast cancer cells did not perturb the conductance of nanodevices with adsorbed anti-PSMA or nonspecific antibodies. Hence, the conductance change required a specific antigen-antibody complex between the live, intact breast cancer cell and the nanotube surface in blood. We postulate that sensing of breast cancer cell binding is due to cooperative stress on the surface of the nanotubes due to cellular binding to multiple antibodies. The stress on the nanotube is then thought to change its electron transport properties. Five microliter drops of blood from patients with metastatic breast cancer changed nanodevice conductance similarly to 10-100 MCF7 cells. Comparable circulating tumor cell numbers were obtained from 7.5 mL blood draws from the same patients analyzed by EpCAM bead capture and anti-cytokeratin staining. Single wall carbon nanotube-monoclonal antibody nanodevices provide the simplest and quickest method for direct detection of live cancer cells circulating in blood. Supported by a grant from the Breast Cancer Alliance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-72.
Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular Cystic Renal Cell Carcinoma with Focus on Clinical and Pathobiological Aspects. Eur Urol 2013;63:400–1
Authors: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli
Journal: European Urology (2013)
A sclerodermatous syndrome with unusual features following prolonged occupational exposure to organic solvents
Authors: W.W. BOTTOMLEY, R.A. SHEEHAN-DARE, P. HUGHES, W.J. CUNLIFFE
Journal: British Journal of Dermatology (1993)

Journal Article A sclerodermatous syndrome with unusual features following prolonged occupational exposure to organic solvents Get access W.W. BOTTOMLEY, W.W. BOTTOMLEY Department of Dermatology. The General Infirmary. Leeds LS1 3EX, U.K. Dr W.W.Bottomley. The General Infirmary at Leeds. Great George Street. Leeds LS1 3EX. U.K. Search for other works by this author on: Oxford Academic Google Scholar R.A. SHEEHAN‐DARE, R.A. SHEEHAN‐DARE Department of Dermatology. The General Infirmary. Leeds LS1 3EX, U.K. Search for other works by this author on: Oxford Academic Google Scholar P. HUGHES, P. HUGHES University Medical Unit, The Northern General. Sheffield S5 7AU. U.K. Search for other works by this author on: Oxford Academic Google Scholar W.J. CUNLIFFE W.J. CUNLIFFE Department of Dermatology. The General Infirmary. Leeds LS1 3EX, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 128, Issue 2, 1 February 1993, Pages 203–206, https://doi.org/10.1111/j.1365-2133.1993.tb15152.x Published: 01 February 1993 Article history Accepted: 06 September 1992 Published: 01 February 1993
Human and Mouse Granzyme A Induce a Proinflammatory Cytokine Response
Authors: Sunil S. Metkar, Cheikh Menaa, Julian Pardo, Baikun Wang, Reinhard Wallich, Marina Freudenberg, Stephen Kim, Srikumar M. Raja, Lianfa Shi, Markus M. Simon, Christopher J. Froelich
Journal: Immunity (2008)
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
Authors: D S Siegel, P Richardson, M Dimopoulos, P Moreau, C Mitsiades, D Weber, J Houp, C Gause, S Vuocolo, J Eid, T Graef, K C Anderson
Journal: Blood Cancer Journal (2014)

The addition of vorinostat to lenalidomide/dexamethasone represents a novel combination therapy in multiple myeloma (MM), informed by laboratory studies suggesting synergy. This was a phase I, multicenter, open-label, non-randomized, dose-escalating study in patients with relapsed or relapsed and refractory MM. Clinical evaluation, electrocardiogram, laboratory studies and adverse events were obtained and assessed. The maximum-tolerated dose was not reached owing to a non-occurrence of two dose-limiting toxicities per six patients tested at any of the dosing levels. Patients tolerated the highest dose tested (Level 5) and this was considered the maximum administered dose: at 400 mg vorinostat on days 1-7 and 15-21, 25 mg lenalidomide on days 1-21 and 40 mg dexamethasone on days 1, 8, 15 and 22, per 28-day cycle. Drug-related adverse events were reported in 90% of patients serious adverse experiences were reported in 45% of the patients and 22% of all patients had adverse experiences considered, possibly related to study drug by the investigators. A confirmed partial response or better was reported for 14/30 patients (47%) evaluable for efficacy, including 31% of patients previously treated with lenalidomide. Vorinostat in combination with lenalidomide and dexamethasone proved tolerable with appropriate supportive care, with encouraging activity observed.
Dose-Related Effects of Cigarette Smoking on Olfactory Function
Authors: Richard E. Frye
Journal: JAMA (1990)

Little is known about the influence of cigarette smoking on the ability to smell; previous studies on this topic have led to contradictory findings and have failed to take into account smoking dose and duration. In the present study, the 40-odorant University of Pennsylvania Smell Identification Test was administered to 638 subjects for whom detailed smoking histories were available. Smoking was found to be adversely associated with odor identification ability in a dose-related manner in both current and previous cigarette smokers. Among previous smokers, improvement in olfactory function was related to the time elapsed since the cessation of smoking. Logistic regression analysis found current smokers to be nearly twice as likely to evidence an olfactory deficit than persons who have never smoked. Overall, the data suggest that (1) smoking causes long-term but reversible adverse effects on the ability to smell and (2) the failure of some studies to demonstrate smoking effects may be caused by the inclusion of persons with a history of smoking in the nonsmoking groups.
Overcoming the emotion experience/expression dichotomy
Authors: Fausto Caruana, Vittorio Gallese
Journal: Behavioral and Brain Sciences (2012)

Abstract We challenge the classic experience/expression dichotomous account of emotions, according to which experiencing and expressing an emotion are two independent processes. By endorsing Dewey's and Mead's accounts of emotions, and capitalizing upon recent empirical findings, we propose that expression is part of the emotional experience. This proposal partly challenges the purely constructivist approach endorsed by the authors of the target article.
The Cause and Pathogenesis of the Eosinophilia-Myalgia Syndrome
Authors: John Varga, Jouni Uitto, Sergio A. Jimenez
Journal: Annals of Internal Medicine (1992)

Objective: To review recent advances in the understanding of the cause and pathogenesis of the eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Data Sources: Studies published from 1989 to 1991 were identified using a MEDLINE literature search. Additional references were selected from the bibliographies of identified articles. Data Synthesis: The eosinophilia-myalgia syndrome was epidemiologically associated with ingestion of L-tryptophan-containing preparations. Analysis of case-associated lots of L-tryptophan has revealed several chemical impurities. One of these, labeled "peak E," is an unusual dimeric form of L-tryptophan (1,1′-ethylidenebis[tryptophan]), and its presence is associated with the eosinophilia-myalgia syndrome (P = 0.022). Evidence of abnormal metabolism of tryptophan has been found in some patients with the syndrome. Eosinophil activation and the release of major basic protein and other eosinophil-derived toxic proteins into the extracellular space is a striking feature in the eosinophilia-myalgia syndrome and implicates eosinophils or their products in the pathogenesis. Mononuclear cell activation and infiltration of various affected tissues as well as fibrosis of the integument and of the connective tissue components of blood vessels, nerves, and muscles are additional frequent findings. Conclusions: Current evidence suggests that the epidemic of the eosinophilia-myalgia syndrome was caused by contaminated L-tryptophan preparations originating from a single manufacturer. Peak E or other, as yet unidentified, contaminants may trigger activation of eosinophils and inflammatory cells and increase biosynthesis of connective tissue components, resulting in the clinical and pathologic manifestations of the eosinophilia-myalgia syndrome. Further studies of the interaction of eosinophils, inflammatory cells, and fibroblasts may increase the understanding of the pathogenesis of the eosinophilia-myalgia syndrome. The insights gained from the epidemic may be applicable to more common idiopathic diseases associated with eosinophilia and fibrosis.
Oh, to Live in an Age When Men Had Breasts . . .
Authors: Scott W Wright
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
3. TOXICITY OF PRIMAQUINE IN CAUCASIANS
Authors: Charles B. Clayman
Journal: JAMA (1952)

Primaquine, 8-(4-amino-1-methylbutylamino)-6-methoxyquinoline,<sup>1</sup>a new curative agent for vivax malaria, has recently been extensively tested in the Armed Forces. Since mid-December, 1951, veterans returning from Korea have received 15 mg. of primaquine base once daily for two weeks aboard Military Sea Transport ships after termination of weekly chloroquine (aralen®) suppression at the time of embarkation.<sup>2</sup>Chloroquine remains in the blood in effective concentration for several weeks; it suppresses clinical symptoms by eliminating the erythrocytic forms of the malaria parasite but does not prevent subsequent relapses. Relapses can be prevented, however, by the administration of primaquine, which acts primarily against the exoerythrocytic parasites. Thus, combined action of the two drugs has been exploited during the transpacific voyage to achieve radical cure of vivax infections before symptoms have developed. Primaquine, combined with chloroquine, has also been employed extensively in treating clinical attacks of vivax malaria in Army installations in the United
Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo
Authors: T A Navas, A N Nguyen, T Hideshima, M Reddy, J Y Ma, E Haghnazari, M Henson, E G Stebbins, I Kerr, G O'Young, A M Kapoun, S Chakravarty, B Mavunkel, J Perumattam, G Luedtke, S Dugar, S Medicherla, A A Protter, G F Schreiner, K C Anderson, L S Higgins
Journal: Leukemia (2006)
A Novel, High Endothelial Venule–Specific Sulfotransferase Expresses 6-Sulfo Sialyl Lewisx, an L-Selectin Ligand Displayed by CD34
Authors: Nobuyoshi Hiraoka, Bronislawa Petryniak, Jun Nakayama, Shigeru Tsuboi, Misa Suzuki, Jiunn-Chern Yeh, Dai Izawa, Toshiyuki Tanaka, Masayuki Miyasaka, John B Lowe, Minoru Fukuda
Journal: Immunity (1999)